Affimed NVNASDAQ:AFMD
- LAST PRICE5.0700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.9700/ 3
- Ask / Lots6.7300/ 3
- Open / Previous Close0.0000 / 5.0700
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AFMD |
|---|---|---|
| 09:32 ET | 752 | 5.29 |
| 09:39 ET | 1000 | 5.235 |
| 09:52 ET | 1220 | 5.29 |
| 10:30 ET | 7127 | 5.19 |
| 10:50 ET | 100 | 5.2745 |
| 10:55 ET | 1700 | 5.24 |
| 11:00 ET | 200 | 5.24 |
| 11:44 ET | 9300 | 5.2699 |
| 11:47 ET | 1000 | 5.2695 |
| 11:56 ET | 100 | 5.255 |
| 12:12 ET | 500 | 5.24 |
| 12:38 ET | 100 | 5.25 |
| 12:45 ET | 100 | 5.21 |
| 12:48 ET | 100 | 5.21 |
| 12:50 ET | 512 | 5.2 |
| 12:52 ET | 569 | 5.18 |
| 01:03 ET | 100 | 5.16 |
| 01:14 ET | 250 | 5.2296 |
| 01:37 ET | 100 | 5.17 |
| 01:44 ET | 900 | 5.1 |
| 01:46 ET | 18700 | 5.17 |
| 01:48 ET | 13400 | 5.2 |
| 01:50 ET | 1500 | 5.19 |
| 02:11 ET | 100 | 5.14 |
| 02:15 ET | 100 | 5.21 |
| 02:27 ET | 100 | 5.15 |
| 02:31 ET | 100 | 5.21 |
| 02:44 ET | 100 | 5.15 |
| 02:47 ET | 875 | 5.153 |
| 03:00 ET | 100 | 5.15 |
| 03:05 ET | 500 | 5.15 |
| 03:14 ET | 200 | 5.18 |
| 03:30 ET | 300 | 5.13 |
| 03:34 ET | 798 | 5.18 |
| 03:41 ET | 2428 | 5.19 |
| 03:50 ET | 4143 | 5.1 |
| 03:54 ET | 3400 | 5.1 |
| 03:56 ET | 3079 | 5.1 |
| 03:57 ET | 2611 | 5.1 |
| 03:59 ET | 1254 | 5.07 |
Apr 1, 2024
DJ Affimed Is Maintained at Overweight by Wells Fargo, from 11:48AM ET on Monday Apr 01, 2024 by Dow Jones
11:48AM ET on Monday Apr 01, 2024 by Dow JonesDJ Affimed Is Maintained at Hold by Stifel, from 11:03AM ET on Monday Apr 01, 2024 by Dow Jones
11:03AM ET on Monday Apr 01, 2024 by Dow JonesDJ Affimed Is Maintained at Buy by HC Wainwright & Co., from 6:46AM ET on Monday Apr 01, 2024 by Dow Jones
6:46AM ET on Monday Apr 01, 2024 by Dow Jones
Mar 28, 2024
Affimed Reports 2023 Financial Results and Operational Progress, from 6:30AM ET on Thursday Mar 28, 2024 by Dow Jones
6:30AM ET on Thursday Mar 28, 2024 by Dow JonesPress Release: Affimed Reports 2023 Financial Results and Operational Progress, from 6:30AM ET on Thursday Mar 28, 2024 by Dow Jones
6:30AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Affimed NV | 77.2M | -0.7x | --- |
Atara Biotherapeutics Inc | 82.6M | -0.3x | --- |
Curis Inc | 89.7M | -1.7x | --- |
Ikena Oncology Inc | 60.8M | -0.8x | --- |
LAVA Therapeutics NV | 74.4M | -1.8x | --- |
Clearside Biomedical Inc | 98.6M | -2.5x | --- |
Company Information
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Contact Information
- Headquarters
- Gottlieb-Daimler-Strasse 2MANNHEIM, Germany 68165
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Supervisory Board
- Thomas Hecht
- Chief Executive Officer, Member of the Management Board
- Adi Hoess
- Chief Financial Officer, Co-President Affimed Inc, Member of the Management Board
- Angus Smith
- Chief Operating Officer, Member of the Management Board
- Wolfgang Fischer
- Chief Scientific Officer, Member of the Management Board
- Arndt Schottelius
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $77.2M |
|---|---|
Revenue (TTM) | $8.8M |
Shares Outstanding | 15.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.06 |
EPS | $-7.55 |
Book Value | $4.12 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 8.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,288.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
